Drug intelligence / Profile preview

JY23

Development stage: Preclinical
Lead developer: Jiuyuan Gene Engineering
Modality: Recombinant Proteins and Enzymes
Administration: Implant

Overview

**JY23** is an investigational orthopedic drug-device combination developed by Hangzhou Jiuyuan Genetic Biopharmaceutical for bone repair. The product incorporates recombinant human bone morphogenetic protein-2, an osteoinductive growth factor, with multiple osteoconductive biomaterials to support bone regeneration at sites of bone injury or defect. Public company disclosures describe JY23 as an implantable next-generation bone-repair material that has completed registration testing and entered product-registration review in China.

Other names: JY-23JY23JY 23rhBMP-2-integrated pluripotent biological bonerhBMP2-integrated pluripotent biological bonerhBMP 2-integrated pluripotent biological bone

Targets

BMPR1ABMPR1BBMPR2 (Bone morphogenetic protein receptor type II)

Beyond the preview

Go deeper on JY23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY23.

Explore the full profile